# Oral Zinc Supplementation to Enhance Botulinum Neurotoxin Response

> **NCT05095493** · NA · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 54 (actual)

## Conditions studied

- Dystonia, Focal

## Interventions

- **DIETARY_SUPPLEMENT:** Zinc Acetate
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT05095493
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-01
- **Primary completion:** 2014-10-31
- **Final completion:** 2014-10-31
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05095493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05095493, "Oral Zinc Supplementation to Enhance Botulinum Neurotoxin Response". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05095493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*